APSR logo

A selection of publications with educational value in

Interstitial Lung Disease

Most recently added articles listed at the top

  • Table 1
    (Click image to enlarge)
    Serial chest CT in cryptogenic organizing pneumonia: Evolutional changes and prognostic determinants Man P Chung, Bo D Nam, Kyung S Lee, Joungho Han, Jai S Park, Jung H Hwang, Min J Cha and Tae J Kim (DOI: 10.1111/resp.13188)
    onlinelibrary.wiley.com/doi/10.1111/resp.13188/full (Mar 2018)

    Comment by Dr Mark Lavercombe:
    This paper describes the radiological follow-up of patients treated for cryptogenic organising pneumonia and demonstrates a high proportion of patients have residual radiologic abnormality. Several factors associated with persisting abnormalities are identified, including extent of consolidation and treatment duration.

  • Two position statements on interstitial lung disease

    • Figure 1
      (Click image to enlarge)
      Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia: Helen E Jo, Lauren K Troy, Gregory Keir, Daniel C Chambers, Anne Holland, Nicole Goh, Margaret Wilsher, Sally de Boer, Yuben Moodley, Christopher Grainge, Helen Whitford, Sally Chapman, Paul N Reynolds, Ian Glaspole, David Beatson, Leonie Jones, Peter Hopkins, Tamera J Corte
      10.1111/resp.13146 (Oct 2017)

    • Figure 1
      (Click image to enlarge)
      The interstitial lung disease multidisciplinary meeting: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia: Jyotika D Prasad, Annabelle Mahar, Jane Bleasel, Samantha J Ellis, Daniel C Chambers, Fiona Lake, Peter M A Hopkins Tamera J Corte, Heather Allan, Ian N Glaspole
      10.1111/resp.13163 (Oct 2017)
    • Managing patients with interstitial lung disease: Two more pieces of the puzzle: Francesco Macagno, Paolo Maria Leone, Luca Richeldi
      10.1111/resp.13195 (Nov 2017)

  • Figure 2
    (Click image to enlarge)
    CT-determined pulmonary artery to aorta ratio as a predictor of elevated pulmonary artery pressure and survival in idiopathic pulmonary fibrosis: Mitsuaki Yagi, Hiroyuki Taniguchi, Yasuhiro Kondoh, Masahiko Ando, Tomoki Kimura, Kensuke Kataoka, Taiki Furukawa, Atsushi Suzuki, Takeshi Johkoh & Oshinori Hasegawa.
    10.1111/resp.13066 (Oct 2017)

    Comment by Dr Mark Lavercombe:
    The PA:A ratio as measured on chest CT scan has been demonstrated to predict pulmonary hypertension in some studies. In this cohort PA:A > 0.9 is found to predict both elevated mPAP and survival in patients with idiopathic pulmonary fibrosis.


  • (Click image to enlarge)
    Frailty is common and strongly associated with dyspnoea severity in fibrotic interstitial lung disease, Kathryn M Milne, Joanne M Kwan, Sabina Guler, Tiffany A Winstone, Angela Le, Nasreen Khalil, Pat G Camp, Pearce G Wilcox & Christopher J Ryerson
    10.1111/resp.12944 (May 2017)

    Prognosis in patients with fibrotic interstitial lung diseases can vary significantly. In this study, the authors demonstrate that Frailty is highly prevalent in a cohort of patients with fibrotic ILD and strongly associated with dyspnoea severity. The authors propose a potential role for frailty assessment in identifying patients at risk of complications from invasive procedures or medical therapies, and/or mortality.

  • Pulmonary Rehabilitation Guidelines for Australia and New Zealand Jennifer A Alison, Zoe J McKeough, Kylie Johnston, Renae J McNamara, Lissa M Spencer, Sue C Jenkins, Catherine J Hill, Vanessa M McDonald, Peter Frith, Paul Cafarella, Michelle Brooke, Helen L Cameron-Tucker, Sarah Candy, Nola Cecins, Andrew S L Chan, Marita T Dale, Leona M Dowman, Catherine Granger, Simon Halloran, Peter Jung, Annemarie L Lee, Regina Leung, Tamara Matulick, Christian Osadnik, Mary Roberts, James Walsh, Sally Wootton, Anne E Holland, on behalf of the Lung Foundation Australia and the Thoracic Society of Australia and New Zealand 10.1111/resp.13025 (Apr 2017)

    The aim of these Guidelines is to provide evidence-based recommendations for the practice of pulmonary rehabilitation (PR) specific to Australian and New Zealand healthcare contexts.

    These first-ever pulmonary rehabilitation Guidelines for Australia and New Zealand were launched (24-28 March 2017) at the TSANZSRS Annual Scientific Meeting in Canberra, Australia (24-28 March 2017), and were drawn up following a systematic review of over 275 clinical trials.

    The Guidelines recommend that all COPD patients should be offered pulmonary rehabilitation regardless of their disease severity.

    See the full Editorial for these important Guidelines at onlinelibrary.wiley.com/doi/10.1111/resp.13039/full


  • (Click image to enlarge)
    Bronchoscopy assessment of acute respiratory failure in interstitial lung disease Antonella Arcadu & Teng Moua DOI: 10.1111/resp.12909
    onlinelibrary.wiley.com/doi/10.1111/resp.12909/full (Feb 2017)

    Comment by Dr Mark Lavercombe:
    This study examines the utility of bronchoscopy in patients admitted with acute exacerbations of interstitial lung disease. Although a relatively low diagnostic yield is identified, significant potential complications are noted and there is no in-hospital mortality benefit seen in those undergoing the procedure.


  • (Click image to enlarge)
    Clinical impact of the interstitial lung disease Multidisciplinary service, Jo et al. DOI: 10.1111/resp.12850
    onlinelibrary.wiley.com/doi/10.1111/resp.12850/full (Jul 2016)

    Comment by Dr Mark Lavercombe:
    This study demonstrates that assessment of the diagnosis and management of interstitial lung diseases by an expert multidisciplinary panel can potentially make a major contribution to patient outcomes. A significant proportion of patients is re-classified after MDT discussion, leading to changes in management. Longer term follow-up of patient outcomes might add weight to the use of MDT discussions.

  • Effect of long-term treatment with corticosteroids on skeletal muscle strength, functional exercise capacity and health status in patients with interstitial lung disease. Hanada et al.
    onlinelibrary.wiley.com/doi/10.1111/resp.12807/abstract (May 2016)
    (FREE access: Editor's Choice; Editorial: onlinelibrary.wiley.com/doi/10.1111/resp.12843/abstract)

  • Interstitial lung disease associated with gemcitabine: A Japanese retrospective cohort study. Hamada et al.
    onlinelibrary.wiley.com/doi/10.1111/resp.12665/abstract (Nov 2015)